Cardiff Oncology (CRDF) Net Income towards Common Stockholders (2011 - 2026)
Cardiff Oncology (CRDF) posted Net Income towards Common Stockholders of -$7.2 million for Q4 2025, up 35.88% sequentially from -$11.3 million in Q3 2025, and up 38.75% YoY from -$5.2 million in Q4 2024.
Cardiff Oncology (CRDF) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Net Income towards Common Stockholders for 15 years, with the latest figure at -$7.2 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 38.75% year-over-year to -$7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$45.9 million (down 0.93% YoY) and the FY2025 annual result came in at -$45.9 million, down 0.93% from the prior year.
- Net Income towards Common Stockholders grew to -$7.2 million in Q4 2025 per CRDF's latest filing, from -$11.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$5.2 million in Q1 2021 and troughed at -$13.9 million in Q2 2025.
- A 5-year average of -$10.0 million and a median of -$10.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 112.13% in 2022, then surged 38.75% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$9.4 million in 2021, then gained by 7.89% to -$8.7 million in 2022, then fell by 7.35% to -$9.3 million in 2023, then dropped by 26.22% to -$11.8 million in 2024, then soared by 38.75% to -$7.2 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.2 million, -$11.3 million, and -$13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -9.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.24 Mn |
| Dec 31, 2025 | -7.22 Mn |
| Sep 30, 2025 | -11.26 Mn |
| Jun 30, 2025 | -13.95 Mn |
| Mar 31, 2025 | -13.44 Mn |
| Dec 31, 2024 | -11.79 Mn |
| Sep 30, 2024 | -11.86 Mn |
| Jun 30, 2024 | -11.78 Mn |
| Mar 31, 2024 | -10.02 Mn |
| Dec 31, 2023 | -9.34 Mn |
| Sep 30, 2023 | -9.74 Mn |
| Jun 30, 2023 | -11.16 Mn |
| Mar 31, 2023 | -11.23 Mn |
| Dec 31, 2022 | -8.70 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -10.45 Mn |
| Mar 31, 2022 | -11.00 Mn |
| Dec 31, 2021 | -9.45 Mn |
| Sep 30, 2021 | -6.92 Mn |
| Jun 30, 2021 | -6.76 Mn |